Subscribe
gavel-istock-174197278
Mari / iStockphoto.com
10 February 2017Americas

Sanofi and Regeneron secure stay of Praluent injunction

Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent (alirocumab) injection.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi, Regeneron prevail against Amgen at EPO
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Federal Circuit vacates Amgen injunction in Sanofi suit
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Sanofi, Regeneron prevail against Amgen at EPO
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Federal Circuit vacates Amgen injunction in Sanofi suit
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.

More on this story

Americas
Sanofi, Regeneron prevail against Amgen at EPO
30 October 2020   French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Federal Circuit vacates Amgen injunction in Sanofi suit
6 October 2017   The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?